SS-31 + MOTS-c with NAD+ The Mitochondrial Peptide Stack — Full Protocol Guide

SS-31 and MOTS-c with NAD+: A Protocol for Energy Restoration

Difficult-to-explain chronic fatigue is becoming more common. Long COVID, GLP-1-driven weight loss with sustained caloric deficits, and persistent oxidative stress converge on an energy-production bottleneck. Under-fueling, thyroid drag, inflammation, poor sleep, post-viral stress, GLP-1 titration, and overtraining can create the same pattern: chronic fatigue, metabolic inflexibility, and slow recovery when cells cannot turn fuel into usable ATP fast enough.

The Mitochondrial Peptide Stack is an 8–12+ week SS-31, MOTS-c, and NAD+ protocol built for that bottleneck. SS-31 begins first with NAD+ running as support; MOTS-c enters in week 2 to build capacity on a steadier foundation.

The practical case for the protocol is strongest in people experiencing GLP-1 fatigue, where rapid caloric deficit from semaglutide, tirzepatide, or retatrutide can strain energy capacity. Retatrutide adds a measured hepatic-fat-oxidation signal; using this stack to correct the downstream fatigue remains the protocol synthesis.¹² ¹³

Jump to protocol | Where to buy →

What Is a Mitochondrial Peptide Stack?

The stack combines three compounds because mitochondrial output depends on three layers: structure, signaling, and redox support. These determine whether mitochondria can keep up with the work being asked of them.

SS-31 protects the inner membrane where energy is made, the part that degrades with age, inflammation, and oxidative stress (cardiolipin binding). MOTS-c is part of the body’s exercise-response system: mitochondria release it during physical stress, telling cells to build more capacity and shift how they use energy (AMPK activation). NAD+ supplies the redox currency both processes spend, and its availability declines with age and chronic inflammatory load.

Evidence Status

FoxAI developed the Mito Stack Protocol by combining the available evidence for each component with endogenous physiology, published protocols, and mechanistic systems-biology. The complete three-component stack has not been tested in a randomized trial.¹¹

The Three Axes of Mitochondrial Health

Component 1: SS-31 — Membrane Repair

Every mitochondrion has an inner membrane where energy production happens. That membrane depends on a specific molecule — cardiolipin — to hold the energy-producing machinery in place. As cardiolipin degrades from age and oxidative stress, the machinery loosens. Energy output drops. Waste products (reactive oxygen species) spike. The mitochondrion starts costing more to run than it produces.

SS-31 (also called elamipretide) stabilizes cardiolipin directly — tightening the energy-producing chain so it runs cleanly instead of leaking. The best fit is a system where that membrane is already stressed: aging, post-viral fatigue, overtraining, metabolic stress, or a known mitochondrial condition. When mitochondria are already young and healthy, there may be less damaged membrane for SS-31 to protect.¹

SS-31 has the deepest human trial record of the mitochondrial peptides covered here. Its FDA approval is narrow: Barth syndrome, based on an accelerated-approval package that included a randomized TAZPOWER crossover that missed both primary endpoints and a longer open-label extension that reported sustained functional and cardiac changes. MMPOWER-3 in primary mitochondrial myopathy also missed its primary endpoint, with subgroup signals that remain specific to that disease cohort.²

See SS-31 guide for complete coverage.

Component 2: MOTS-c — Metabolic Reprogramming

The body already makes MOTS-c — mitochondria release it during exercise. It is the signal that tells cells to adapt: build more mitochondria, get better at burning fat, and handle glucose more efficiently. Exercise raises plasma MOTS-c about 1.5–1.6-fold, while levels measured in skeletal muscle rise about 11.9-fold.⁴

Where SS-31 protects existing mitochondria, MOTS-c tells cells to build more capacity. It triggers the same cellular response endurance training does through AMPK signaling, helping cells build new mitochondria and shift toward more flexible fuel use. This is why MOTS-c fits training plateaus, GLP-1 fatigue, post-viral drag, and metabolic-flexibility work.³

Native MOTS-c human outcome data is still developing. The strongest current anchors are the original Cell Metabolism discovery work, human exercise physiology, and the completed Phase 1 registration for CB4211, an engineered analog whose public registry record has no posted results. Native MOTS-c and CB4211 are not interchangeable; the analog trial supplies adjacent safety-class context, not native-peptide outcome data.⁵

See MOTS-c guide for more.

Component 3: NAD+ — Cellular Fuel

NAD+ is the redox currency cells spend to make energy, repair damage, regulate inflammation, and maintain circadian timing. Its availability declines with age and can fall faster under chronic stress and inflammation. When the pool is low, the same mitochondrial signal can land poorly because the cell lacks the currency to act on it.⁶

Restoring NAD+ does not create energy out of nothing. It removes a bottleneck: cells can turn fuel into ATP more efficiently, fund repair work, and tolerate training or deficit pressure with less crash.

Oral precursors like NR and NMN are legitimate tools for daily pool support. Injectable NAD+ is mostly broken down outside cells into usable precursors and creates a stronger pulsed exposure.⁷ FoxAI protocols often prefer IM for active rebuilds; SubQ runs 50–100 mg per dose, split into injections of 50 mg or less, when irritation is managed; above 100 mg use IM.

The injectable routes picked up their first controlled human data in 2026: a small double-blind trial (45 people, nine arms) gave 100 mg NAD+ by IM, IV, and SC across three days and found all three tolerated. That covers the lower end of the dose used here. It does not cover delivery: the trial held back its blood-NAD+ measurement, so how much reaches tissue by IM or SC is still open, and the 200 mg end of this range remains practice-derived.

See NAD+ Guide for a deep dive.

MOTS-c and SS-31: How They Work Together

MOTS-c and SS-31 both target mitochondria, but they do different jobs. MOTS-c is the adaptation signal. SS-31 is the structural support.

Why Combine MOTS-c and SS-31?

SS-31 is used to stabilize existing mitochondria that are struggling, reducing electron leak and oxidative stress. Once the structure is steadier, MOTS-c is used to signal for more capacity and better fuel flexibility.

Together, they cover two different bottlenecks: SS-31 protects the machinery, while MOTS-c tells the system to adapt. NAD+ is added because both processes spend redox currency.

When ATP production clears the cell’s maintenance demand, more energy becomes available for downstream repair. FoxAI uses that threshold to explain the reported shift from "managing decline" to recovering more consistently; timing and magnitude vary.

8–12+ Week Mito Stack Protocol

Standard course: 8–12+ weeks. SS-31 runs daily through week 8; after that, continue daily while the response is still building or move to 2–3× weekly once stable. Maintenance protocols pulse MOTS-c alongside NAD+ at 100–250 mg total weekly.¹¹

MOTS-c enters in week 2 once the opening SS-31 response is stable. If pronounced fatigue or local reactions persist, the start moves to week 3.

Critical Support: daily electrolytes and zone-2 cardio early on, resistance training and protein ≥1.6 g/kg through the build phase, and glycine + collagen layered in as repair support.

Why each compound is scheduled the way it is

The three components are on the calendar for three different reasons, and knowing which is which tells you what to do when the stack underdelivers.

The practical upshot: raising the dose is the wrong first move for two of the three. SS-31 needs time, MOTS-c needs a demand, and only NAD+ responds to a supply question — and even there, consistency usually beats a bigger number.

This scheduling logic is read off mechanism and animal time-course work, not from a trial comparing schedules. No such trial exists for any of the three.

Timeline of Effects

This is the expected FoxAI sequence, not a trial-measured timeline.

Where to buy SS-31, MOTS-c, and NAD+

Please read through PeptideFox’s sourcing guide. Our stance is toward quality, safety, and accountability — therefore, we advise against social-media based sourcing and direct import through Chinese vendors.

SS-31, which is FDA approved as Forzinity, is difficult to source without a prescription and we are unable to provide guidance on a reliable research-use-only source.

MOTS-c is available through Research Use Only vendors. For NAD+, as noted, a pre-buffered version is strongly advised.

As of July 2026, we have one fully vetted vendor — Aminos Research — that meets all of our criteria, namely U.S. manufactured (operations directly verified by PeptideFox) with a fully clean 3rd party testing profile (i.e. no anomolies, missing reports, invalidated links). We will continue to assess additional vendors in the coming months.

Buy MOTS-c | Buy Buffered NAD+

Real-World-Evidence: User Reports

How to Reconstitute SS-31, MOTS-c, and NAD+ to Avoid Injection Site Reactions

Both SS-31 and MOTS-c can be injection-site-reactive in protocol use. SS-31 has direct MRGPRX2 mast-cell evidence; for MOTS-c, that mechanism is an inference from its cationic profile and field reaction pattern. FoxAI therefore suggests reconstituting with bacteriostatic 0.9% sodium chloride. The reason is tonicity: plain BAC water is hypotonic, and a hypotonic bolus irritates tissue on its own, while saline matches the fluid it lands in.⁸,¹⁰

No controlled study has compared these diluents for either peptide. This is FoxAI’s formulation synthesis supported by chemistry and repeated field observation.

NAD+ requires a two-step fix. Many reconstituted NAD+ products land around pH 3–4 — highly acidic, which is what causes the burning and/or stinging senstation. NaCl can improve tonicity but cannot raise pH. It is suggested to source NAD+ pre-buffered — which means the pH level has been raised; slower administration, greater dilution, and IM administration can further reduce local burn.⁹

The protocol keeps each compound in a separate vial and syringe. Salt or bicarbonate is never added manually. Sodium chloride can shorten stability in some peptide formulations by increasing aggregation risk. The conservative default is to use a smaller vial, and consume it within 1–2 weeks unless the manufacturer or dispensing pharmacy specifies a different beyond-use date.¹⁰

Need help preparing your peptides? See Peptide Fox’s Reconstitution Guide for step-by-step instructions.

Applications

GLP-1 Fatigue: The Mitochondrial Bottleneck

Fatigue is a recurring adverse event in semaglutide trials and a recurring complaint in FoxAI GLP-1 protocol use. Semaglutide fatigue, tirzepatide fatigue, Ozempic fatigue, and Mounjaro fatigue describe that field pattern rather than one proven mechanism across every drug. Energy can drop during titration or after months of sustained deficit even when weight loss is proceeding.¹²

Why it happens: GLP-1 agonists can lower intake quickly and shift more work toward stored fuel. Retatrutide adds a directly measured hepatic-fat-oxidation signal. If the user is under-eating protein, low on electrolytes, sleeping poorly, pushing titration too fast, or already carrying inflammation or thyroid drag, the bottleneck can land in energy production.¹³

Why the Mito Stack helps: The stack addresses all three failure points:

• SS-31 repairs the membrane structure so electrons flow cleanly (less waste, more output)
• MOTS-c signals cells to build more mitochondria and improve fuel selection (more capacity)
• NAD+ provides the redox currency both processes require (fuel for the machinery)

The goal is simple: help mitochondria execute the fuel shift GLP-1s are creating. That does not replace food, protein, sleep, thyroid assessment, or slower titration. It supports the layer underneath them.

Practical integration: Many users start with NAD+ support first, especially during active titration or a hard caloric deficit. MOTS-c fits when training tolerance, post-exertional fatigue, or metabolic flexibility is the issue. SS-31 is the escalation layer when recovery from exertion remains slow or the fatigue pattern looks more structural than simply under-fueled.

For a complete breakdown of why each GLP-1 compound causes different types of fatigue — and the full intervention hierarchy from protein to mitochondrial support — see Why GLP-1 Medications Make You Tired. For retatrutide-specific NAD+ implementation, see the Retatrutide + NAD+ Protocol.

Injury recovery

The Mito-Stack provides the ATP foundation that tissue repair requires. In injury protocols, NAD+ can start early as the energy layer; SS-31 and MOTS-c become more relevant when fatigue, post-exertional drag, or mitochondrial recovery remains the limiter after vascular repair is underway. See our injury recovery protocol for more detail.

Longevity and anti-aging

By sustaining sirtuin activity, supporting DNA repair, and maintaining mitochondrial density, the Mito-Stack addresses the metabolic decline that underlies aging.

Side Effects and Safety

SS-31: FDA approved narrowly for Barth syndrome. Injection-site irritation, bruising, and induration are the main practical issues, especially at higher concentration or larger volume.²

MOTS-c: FoxAI protocol reports commonly describe injection-site reactions. Fatigue or a glucose-dip feeling can occur if dosing is too fasted, calories are too low, or the user is methylation-sensitive.

NAD+: Slow injection rates reduce flushing, nausea, dizziness, and chest-pressure sensations. IM is preferred for active rebuilds; SubQ runs 50–100 mg per dose, split into injections of 50 mg or less.⁷,⁹

Contraindications: Active malignancy, pregnancy or breastfeeding, acute infection or uncontrolled inflammation, and chemotherapy regimens that depend on NAD+ depletion.

Cautions: Severe renal impairment changes SS-31 exposure; the approved Barth regimen is reduced in severe kidney impairment rather than treated as a blanket contraindication. Heart failure, significant arrhythmia history, recent cardiac events, and uncontrolled hypertension are the profiles that warrant medical oversight. For methylation-sensitive users, MTHFR status is one modifier rather than a stand-alone rule; FoxAI protocols open lower when low B12 or folate status, headaches, anxiety, insomnia, or post-dose crash are also present.²

Monitoring: The standard panel is baseline and month-2 checks for CMP, lipids, and hs-CRP.

FAQ

Related Topics

• NAD+ Guide: Complete NAD+ overview
• SS-31 Guide: Elamipretide — Cardiolipin stabilizer at the core of the stack
• MOTS-c Guide: Deep dive on MOTS-c
• MOTS-c with NAD+ Stack: A lighter stack for energy when SS-31 is not needed
• Circadian Reset Protocol: How NAD+/MOTS-c support the circadian clock
• Peptide Stacking Guide: How the Mito Stack fits into the 5-axis stacking framework
• Retatrutide + NAD+ Protocol: GLP-1 with metabolic support
• GLP-1 Fatigue — Addressing the 3-6 month wall with the Mito Stack

References

SS-31

¹ Birk AV, et al. The mitochondria-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261. PMC3752943

² U.S. Food and Drug Administration. Forzinity integrated review: SPISC-101 healthy-adult PK at 6 mg daily for seven days, the elamipretide clinical program, injection-site reactions, renal dose adjustment, and Barth syndrome approval. 2025. FDA integrated review

MOTS-c

³ Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. DOI: 10.1016/j.cmet.2015.02.009

⁴ Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. DOI: 10.1038/s41467-020-20790-0

⁵ CB4211 Phase 1a/1b registry record. The study tested an engineered MOTS-c analog; the public record does not post results. ClinicalTrials.gov NCT03998514

NAD+

⁶ Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22:119-141. PMC7963035

⁷ Grant R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6-hour intravenous infusion of NAD+. Front Aging Neurosci. 2019;11:257. PMC6751327

Reconstitution and tolerability

⁸ Sullivan A, Bergheanu SC, Kropp LE, et al. Interventions with potential to mitigate injection-site reactions following subcutaneous elamipretide administration: a Phase 1 crossover study. Arch Microbiol Immunol. 2023;7:306-317. Full text

⁹ St Clair-Jones A, et al. Understanding and minimizing injection-site pain following subcutaneous administration. Rheumatol Ther. 2020;7:741-757. PMC7672413

¹⁰ Ouberai MM, Dos Santos ALG, Kinna S, et al. Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly. Nat Commun. 2017;8:1026. DOI: 10.1038/s41467-017-01114-1

Protocol and GLP-1 context

¹¹ FoxAI protocol and formulation synthesis. The 8–12+ week sequence and reconstitution preferences combine per-compound physiology, formulation chemistry, published protocols, and observed use. No randomized trial has tested the complete stack, the same-time administration question, or the preferred diluents against one another.

¹² Sillassen L, et al. Safety of semaglutide: a systematic review and meta-analysis of 50 randomized trials. BMC Med. 2025. PMC12642075

¹³ Retatrutide hepatic oxidation — Sanyal AJ, et al. measured liver-fat and β-hydroxybutyrate changes: 10.1038/s41591-024-03018-2. Pearson MJ, et al. measured the lipid and metabolite fingerprint: 10.1210/clinem/dgag201. These establish Retatrutide’s hepatic FAO demand; no trial has tested SS-31, MOTS-c, or injected NAD+ as the downstream fatigue intervention.